Supriya Lifescience Ltd

Supriya Lifesci. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Supriya Lifescience Ltd

₹
- close price
supriyalifescience.com BSE: 543434 NSE: SUPRIYA
About

Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.[1]

Key Points

Niche Products Offerings[1]
Supriya Lifescience Ltd. has a niche product basket of 40+ APIs and is a global leader in Anti-histamines, anti-allergy, Vitamins, Anti-Asthmatics, & Anesthetics. They utilize a backward-integrated model for 15 products and possess the ability to handle complex chemistries and controlled substances.

Website BSE NSE
  • Market Cap ₹ Cr.
  • Current Price ₹
  • High / Low ₹ /
  • Stock P/E
  • Book Value ₹
  • Dividend Yield %
  • ROCE %
  • ROE %
  • Face Value ₹
Edit ratios

Pros

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare Nifty Microcap 250 Nifty Total Market BSE 1000 Nifty Smallcap 500

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Operating Profit
OPM %
Interest
Depreciation
Profit before tax
Tax %
EPS in Rs
Raw PDF
Upcoming result date: tomorrow

Profit & Loss

Figures in Rs. Crores

Operating Profit
OPM %
Interest
Depreciation
Profit before tax
Tax %
EPS in Rs
Dividend Payout %
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: %
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: %
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: %

Balance Sheet

Figures in Rs. Crores

Equity Capital
Reserves
Total Liabilities
CWIP
Investments
Total Assets

Cash Flows

Figures in Rs. Crores

Net Cash Flow
Free Cash Flow
CFO/OP

Ratios

Figures in Rs. Crores

Debtor Days
Inventory Days
Days Payable
Cash Conversion Cycle
Working Capital Days
ROCE %

Insights

In beta
Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Capacity Utilization
% ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Exports as % of Total Revenue
% ・Standalone data
Installed Reactor Capacity
KLPD ・Standalone data
Backward Integration Contribution to Revenue
% ・Standalone data
Backward Integrated Products
Number ・Standalone data
CEP (Certificates of Suitability)
Number ・Standalone data
Global Footprint (Countries Presence)
Number ・Standalone data
Revenue Contribution - Anesthetic Therapy
% ・Standalone data
Total Customer Base
Number ・Standalone data
USDMF (Active US Drug Master Files)
Number ・Standalone data
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
68.30% 68.30% 68.30% 68.30% 68.30% 68.30% 68.30% 68.30% 68.30% 68.30% 68.30% 68.30%
5.73% 5.35% 4.56% 5.37% 4.95% 6.03% 6.52% 7.19% 6.78% 5.46% 5.19% 5.16%
7.54% 7.17% 5.39% 5.30% 5.48% 5.45% 4.93% 4.26% 4.86% 5.22% 5.00% 5.70%
18.43% 19.19% 21.77% 21.04% 21.27% 20.22% 20.25% 20.25% 20.08% 21.02% 21.49% 20.83%
No. of Shareholders 93,47892,99195,92987,98089,62185,32889,39491,05191,92887,91285,09981,161

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls